Who Paid My Doc
Edna Mora Pinero
Surgical Oncology San Juan, PR Medical Doctor
NPI 1336218700 CMS profile 1027660
261 Calle Duke, San Juan, PR 00927
General payments
$2,138
Research payments
$3,950
Ownership & investment interest
$0
Research they led as principal investigator
$193,001
Through program year 2025, Edna Mora Pinero of San Juan, PR is reported in the CMS Open Payments database as having received $2,138 across 18 general payments and $3,950 in research payments paid to them. Separately, studies naming them as principal investigator received $193,001 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 76th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21 | 1 | |
| 2024 | General | $65 | 1 | |
| 2023 | General | $1,519 | 5 | |
| 2022 | General | $121 | 4 | |
| 2021 | General | $53 | 1 | |
| 2021 | Research | $966 | 2 | |
| 2020 | General | $20 | 1 | |
| 2020 | Research | $1,970 | 2 | |
| 2019 | General | $339 | 5 | |
| 2019 | Research | $1,014 | 1 |
Beside peers
- Edna Mora Pinero
- Surgical Oncology median
- Middle half of Surgical Oncology
- National median
In program year 2025, general payments to Edna Mora Pinero were reported at $21. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.
Show as a table
| Year | Edna Mora Pinero | Surgical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $339 | $236 | $86–$1,064 | $163 |
| 2020 | $20 | $130 | $47–$648 | $114 |
| 2021 | $53 | $160 | $53–$943 | $132 |
| 2022 | $121 | $199 | $76–$782 | $149 |
| 2023 | $1,519 | $246 | $95–$854 | $160 |
| 2024 | $65 | $271 | $106–$1,123 | $164 |
| 2025 | $21 | $288 | $118–$1,346 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
23 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Oncology in Puerto Rico
Pablo Mojica-Manosa
Surgical Oncology · Hato Rey, PR
Jorge Toro-Burguete
Surgical Oncology · Ponce, PR
Kathia Alejandro-Serrano
Surgical Oncology · Manati, PR
Reynold Lopez
Surgical Oncology · San Juan, PR
Carlos Santiago Sanchez
Surgical Oncology · Toa Baja, PR
Angel Rodriguez Rivera
Surgical Oncology · San Juan, PR
Related records
Surgical Oncology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.